MedTrace Logo

Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine

NCT05053321 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2025-07-11

No results posted yet for this study

Summary

This will be an Investigator-initiated pilot study in which participants will be assessed with various scales to measure demoralization, anxiety, depression, and subjective incompetence at baseline and every two weeks after treatment with Valbenazine for a total of 6 weeks. Improvement in TD will be assessed as well and correlated with reduction in demoralization.

Conditions

  • Tardive Dyskinesia

Interventions

DRUG

Valbenazine

All participants will be treated with Valbenazine for 6 weeks.

Sponsors & Collaborators

  • Neurocrine Biosciences

    collaborator INDUSTRY

  • Yale University

    lead OTHER

Principal Investigators

  • John De Figueiredo, MD · Clinical Professor of Psychiatry

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
26 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-18
Primary Completion
2025-10-18
Completion
2025-10-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05053321 on ClinicalTrials.gov